Dipam Patel
Overview
Explore the profile of Dipam Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joshi D, Bahekar R, Soman S, Jadav P, Patel D, Goswami A, et al.
Bioorg Chem
. 2022 Nov;
130:106238.
PMID: 36403335
To discover the best-in-class Bruton's Tyrosine Kinase (BTK) inhibitors, for th treatment of autoimmune disorders like cancer (B-Cell Lymphoma (BCL)) and rheumatoid arthritis (RA), in the present investigation, novel structural...
2.
Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, et al.
Pharmacol Res Perspect
. 2020 Aug;
8(4):e00565.
PMID: 32790160
Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a...
3.
Bahekar R, Panchal N, Soman S, Desai J, Patel D, Argade A, et al.
Bioorg Chem
. 2020 Apr;
99:103851.
PMID: 32334196
Selective inhibition of janus kinase (JAK) has been identified as an important strategy for the treatment of autoimmune disorders. Optimization at the C2 and C4-positions of pyrimidine ring of Cerdulatinib...
4.
Bahekar R, Dave B, Soman S, Patel D, Chopade R, Funde R, et al.
Bioorg Med Chem Lett
. 2019 Apr;
29(11):1313-1319.
PMID: 30975623
PI3Kδ is implicated in various inflammatory and autoimmune diseases. For the effective treatment of chronic immunological disorders such as rheumatoid arthritis, it is essential to develop isoform selective PI3Kδ inhibitors....
5.
Patel V, Joharapurkar A, Kshirsagar S, Patel M, Sutariya B, Patel H, et al.
Can J Physiol Pharmacol
. 2018 Feb;
96(6):587-596.
PMID: 29406832
Nonalcoholic fatty liver disease (NAFLD) is often associated with obesity and type 2 diabetes. Coagonists of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) are under clinical investigation for the...
6.
Patel V, Joharapurkar A, Kshirsagar S, Sutariya B, Patel M, Patel H, et al.
Cardiovasc Hematol Agents Med Chem
. 2018 Jan;
16(1):35-43.
PMID: 29357809
Background: Obesity, diabetes and dyslipidemica are the key pathogenic stimulus that enhances progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Coagonist of Glucagon Like- Peptide-1 (GLP-1) Receptor (GLP-1R) and Glucagon Receptor...
7.
Patel V, Joharapurkar A, Kshirsagar S, Sutariya B, Patel M, Pandey D, et al.
Chem Biol Interact
. 2018 Jan;
282:13-21.
PMID: 29325849
Dyslipidemia enhances progression of atherosclerosis. Coagonist of GLP-1 and glucagon are under clinical investigation for the treatment of obesity and diabetes. Earlier, we have observed that coagonist reduced circulating and...
8.
Patel V, Joharapurkar A, Kshirsagar S, Sutariya B, Patel M, Patel H, et al.
Biomed Pharmacother
. 2017 Dec;
98:364-371.
PMID: 29275178
Coagonists of Glucagon-like peptide-1 (GLP-1) and glucagon receptors are under clinical investigation for treatment of obesity associated with diabetes. In addition to their role in glucose homeostasis, GLP-1 and glucagon...
9.
Patel V, Joharapurkar A, Kshirsagar S, Patel H, Pandey D, Patel D, et al.
Drug Res (Stuttg)
. 2017 Sep;
67(12):730-736.
PMID: 28898910
Hyperlipidemia is often associated with obesity and diabetes, and can lead to serious complications like atherosclerosis and fatty liver disease. Coagonist of GLP-1 and glucagon receptors is a therapy under...
10.
Patel V, Joharapurkar A, Kshirsagar S, Patel H, Pandey D, Patel D, et al.
Drug Res (Stuttg)
. 2017 Apr;
67(6):318-326.
PMID: 28445900
Increased lipid levels in blood contribute to increasing the risk of diabetic complications. Glucagon exerts lipid lowering effects in diabetic state. However, the mechanism behind the lipid reduction by glucagon...